Amphotericin B liposomal indications and usage: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 7: Line 7:
AmBisome is indicated for the following:
AmBisome is indicated for the following:


*:Empirical therapy for presumed fungal infection in febrile, '''[[neutropenic patients]]'''.
*:Empirical therapy for presumed fungal infection in febrile, '''[[Febrile neutropenia|neutropenic fever]]''' patients.


*:Treatment of '''Cryptococcal [[Meningitis]]''' in HIV infected patients.
*:Treatment of '''cryptococcal [[meningitis]]''' in HIV infected patients.
Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate.
Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with AmBisome, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES).


See DOSAGE AND ADMINISTRATION for recommended doses by indication.
*:Treatment of patients with '''[[Aspergillus]]''' species, Candida species and/or '''[[Cryptococcus]]''' species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate.
<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = AMBISOME (AMPHOTERICIN B) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ASTELLAS PHARMA US, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a | publisher =  | date =  | accessdate =  }}</ref>


*:Treatment of '''[[visceral leishmaniasis]]'''. In immunocompromised patients with visceral leishmaniasis treated with AmBisome, relapse rates were high following initial clearance of parasites.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = AMBISOME (AMPHOTERICIN B) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ASTELLAS PHARMA US, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a | publisher =  | date =  | accessdate =  }}</ref>


==References==
==References==

Revision as of 15:46, 5 January 2014

Amphotericin B Liposomal
AMBISOME® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Indications and Usage

AmBisome is indicated for the following:

  • Empirical therapy for presumed fungal infection in febrile, neutropenic fever patients.
  • Treatment of cryptococcal meningitis in HIV infected patients.
  • Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate.
  • Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with AmBisome, relapse rates were high following initial clearance of parasites.[1]

References

  1. ↑ "AMBISOME (AMPHOTERICIN B) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ASTELLAS PHARMA US, INC.]".

Adapted from the FDA Package Insert.

Retrieved from "https://www.wikidoc.org/index.php?title=Amphotericin_B_liposomal_indications_and_usage&oldid=924556"